KEAP1-NFE2L2通路突变定义快速进展性肺腺癌分子亚群
本研究通过扩增子测序分析转移性NSCLC的应激反应通路(SRP)基因突变,发现在Regina Elena队列中KEAP1/NFE2L2突变患者化疗后PFS和OS显著缩短(log-rank p=0.006和0.018),该关联由肺腺癌驱动,并在MSKCC和TCGA队列中验证。
要点
- KEAP1/NFE2L2突变与转移性肺腺癌化疗后更短PFS和OS相关。
- 该突变亚群与TP53突变互斥,并伴pATM/pATR表达升高。
- KEAP1/NFE2L2突变或定义化疗耐药、快速进展的肺腺癌分子亚型。
核心结论
- KEAP1/NFE2L2通路突变是转移性肺腺癌不良预后/预测因子,可能定义化疗耐药和快速进展的分子亚型。
研究设计与样本
- 研究采用基于扩增子的二代测序,在Regina Elena国家癌症研究所队列(n=88)中分析转移性NSCLC患者的应激反应通路基因。
- 同时分析DNA损伤反应基因(TP53、ATM、ATR)突变,并在肺腺癌中检测pATM和pATR表达。
- 使用MSKCC队列(n=1256)和TCGA队列(n=162)验证结果可重复性。
主要发现
- 在Regina Elena队列中,KEAP1/NFE2L2通路突变患者较野生型患者PFS显著缩短(log-rank p=0.006),OS显著缩短(log-rank p=0.018)。
- 该关联由肺腺癌驱动,KEAP1/NFE2L2突变在快速进展者中过表达,与疾病进展和死亡风险增加相关。
- KEAP1/NFE2L2突变肺腺癌显示pATM和pATR表达升高,并与TP53突变互斥。
- MSKCC队列验证KEAP1/NFE2L2突变与更短生存相关(log-rank p<0.001)。
- TCGA队列验证KEAP1/NFE2L2突变与更短生存相关(log-rank p=0.039)。
关键数值与推荐
- Regina Elena队列中KEAP1/NFE2L2突变患者PFS log-rank p=0.006,OS log-rank p=0.018。
- MSKCC队列(n=1256)中KEAP1/NFE2L2突变与生存缩短相关,log-rank p<0.001。
- TCGA队列(n=162)中KEAP1/NFE2L2突变与生存缩短相关,log-rank p=0.039。
临床怎么用
- 对转移性肺腺癌患者可考虑检测KEAP1/NFE2L2通路突变以识别化疗耐药和快速进展风险。
- KEAP1/NFE2L2突变患者可能需要更密切监测或探索替代治疗策略。
局限性
- 研究为回顾性队列分析,样本量有限(Regina Elena队列n=88)。
- 未报告KEAP1/NFE2L2突变对特定化疗方案疗效的预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Molecular characterization studies revealed recurrent kelch like ECH associated protein 1 gene (KEAP1)/nuclear factor, erythroid 2 like 2 gene (NFE2L2) alterations in NSCLC. These genes encode two interacting proteins (a stress response pathway [SRP]) that mediate a cytoprotective response to oxidative stress and xenobiotics. Nevertheless, whether KEAP1/NFE2L2 mutations have an impact on clinical outcomes is unclear. METHODS: We performed amplicon-based next-generation sequencing to characterize the SRP in patients with metastatic NSCLC (Regina Elena National Cancer Institute cohort [n = 88]) treated with first-line chemotherapy. Mutations in the DNA damage response (tumor protein p53 gene [TP53], ATM serine/threonine kinase gene [ATM], and ATR serine/threonine kinase gene [ATR]) were concomitantly analyzed. In lung adenocarcinoma (LAC), we also determined the expression of phosphorylated ataxia telangiectasia mutated kinase and ataxia telangiectasia and Rad3-related protein. Two independent cohorts (the Memorial Sloan Kettering Cancer Center cohort and The Cancer Genome Atlas cohort) with data from approximately 1400 patients with advanced LAC were used to assess the reproducibility of the results. RESULTS: In the Regina Elena National Cancer Institute cohort, patients whose tumors carried mutations in the KEAP1/NFE2L2 pathway had significantly shorter progression-free survival and overall survival than their wild-type counterparts did (log-rank p = 0.006 and p = 0.018, respectively). This association was driven by LAC in which KEAP1/NFE2L2 mutations were overrepresented in fast progressors and associated with an increased risk of disease progression and death. LACs carrying KEAP1/NFE2L2 mutations were characterized by elevated expression of phosphorylated ataxia telangiectasia mutated (pATM) kinase and ataxia telangiectasia and Rad3-related (pATR) protein in association with a pattern of mutual exclusivity with TP53 alterations. The relationship between KEAP1/NFE2L2 mutations and shorter survival was validated in the Memorial Sloan Kettering Cancer Center cohort (n = 1256) (log-rank p < 0.001) and in The Cancer Genome Atlas cohort (n = 162) (log-rank p = 0.039). CONCLUSION: These findings suggest that a mutant SRP represents a negative prognostic/predictive factor in metastatic LAC and that KEAP1/NFE2L2 mutations may define a molecular subtype of chemotherapy-resistant and rapidly progressing LAC.
引用
- Goeman F, De Nicola F, Scalera S, et al. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. J Thorac Oncol. 2019. PMID: 31323387. doi:10.1016/j.jtho.2019.07.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。